Does siRNA-based therapy require pegylated interferon-alfa-2a to cure HBV infection?
- PMID: 39389080
- DOI: 10.1016/S2468-1253(24)00303-0
Does siRNA-based therapy require pegylated interferon-alfa-2a to cure HBV infection?
Conflict of interest statement
I have received grants from Assembly and Blue Jay (to institution); consulting fees from Aligos, Assembly, Blue Jay, GSK, and Zhimeng; and payments or honoraria from Gilead.
Comment on
-
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.Lancet Gastroenterol Hepatol. 2024 Dec;9(12):1121-1132. doi: 10.1016/S2468-1253(24)00237-1. Epub 2024 Oct 8. Lancet Gastroenterol Hepatol. 2024. PMID: 39389081 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources